Canakinumab, mainly used for the treatment of various autoinflammatory diseases and gout, is an innovative biological agent whose unique efficacy has been widely recognized by the international medical community. In China, canakinumab has not yet been marketed and is not included in the medical insurance catalog, so patients are particularly concerned about information such as its price, efficacy, and side effects.
Canakinumab: Instructions, Medical Insurance, Price, Efficacy, and Side Effects
Developed by Novartis of Switzerland, canakinumab is an interleukin-1β blocker, mainly used for the treatment of autoinflammatory periodic fever syndromes, Still's disease, gout, and other diseases.
Overview of Canakinumab Instructions
Canakinumab is in the form of an injection with a specification of 150mg/mL and needs to be used subcutaneously. The recommended dose of canakinumab is based on the patient's weight and disease type, and the specific usage and dosage should follow the doctor's guidance. In China, canakinumab has not been marketed, so patients cannot directly obtain its instructions.
Price of Canakinumab
The price of canakinumab in the international market varies due to factors such as region, sales channel, and purchase volume.
Reference Price in International Market
In different countries or regions, the actual selling price of canakinumab may vary due to factors such as policies, taxes, and market competition.
Domestic Purchase Cost
For domestic patients, since canakinumab has not been marketed, it needs to be obtained through overseas drug purchases or participation in clinical trials. The cost of overseas drug purchases includes the price of the drug itself, international transportation fees, tariffs, and possible agency fees, which makes the actual purchase cost of canakinumab much higher than the reference price in the international market. Patients need to carefully consider when choosing overseas drug purchases.
Efficacy and Side Effects of Canakinumab
Canakinumab has shown significant efficacy in the treatment of various autoinflammatory diseases and gout.
Significant Efficacy of Canakinumab
Clinical studies have shown that canakinumab can effectively reduce the disease activity of patients, relieve pain symptoms, and improve the quality of life of patients. In the treatment of cryopyrin-associated periodic syndromes, canakinumab can significantly reduce the frequency and duration of fever in patients; in the treatment of Still's disease, canakinumab can significantly improve symptoms such as joint swelling and pain in patients.
Side Effects Require Caution
During the use of canakinumab, patients may experience adverse reactions such as injection site reactions, diarrhea, flu-like symptoms, and nausea. Canakinumab may also increase the risk of serious infections in patients, especially for those with a history of infection or low immunity.
Before using canakinumab, patients should inform the doctor in detail about their physical condition and medication history, so that the doctor can formulate a personalized treatment plan and closely monitor the patient's medication response.
